But it is work: My perspective on social media - Volume 30, Issue

When I was asked to write about using social media for work and collaboration, one “professional” social media platform immediately sprang to mind – LinkedIn. This article discusses LinkedIn, one of many social media platforms in a prosperous…

Lingua Franca and Beyond - Volume 30, Issue

Our mentors It is my great pleasure to introduce this article written by Julia Bates from Australia, who in a very personal way describes her journey to becoming a very professional and experienced medical writer – a journey that often went across…

ADHD: A true neurodevelopmental disorder? - Volume 21, Issue

Attention-deficit/hyperactivity disorder (ADHD) is one of the most common childhood disorders. First described in 1798 by Alexander Crichton, ADHD became widely known outside the medical profession with the publication of the story of Fidgety Phil…

Using social media as the patient's voice in the benefit-risk assessment of drugs: Are we ready? - Volume 24, Issue

There is no doubt that the public interest in healthcare-related issues is growing. This, coupled with the surge in the use of social media, leaves the pharmaceutical industry with a set of unique opportunities and challenges. The screening and…

CORE Reference – a tool for modern clinical study reports in an era of increasing transparency and disclosure - Volume 27, Issue

CORE Reference (www.core-reference.org) facilitates the authoring of a content-driven clinical study report (CSR) that is as “public disclosure-ready” as possible. It has potential to increase the quality of final CSRs and enhance consistency within…

Social Media - Volume 30, Issue

Social media

“For many people, the internet can feel like a lonely place. It can feel like… a big, endless, expansive void where you can constantly call out to it but no one’s ever listening. But… I found, in sharing my feelings with the void, event…

The changing face of (benefit-)risk management - Volume 24, Issue

Over the last 20 years the focus of post-approval management of medicines has changed from risk management to the assessment and management of benefit-risk. In the EU this has been reinforced by changes in the legislation underpinning…

GPP3 – what is it, why is it necessary and what is new? - Volume 25, Issue

The good publication practice for pharmaceutical companies (GPP) guidelines were first published in 2003, then revised in 2009 (GPP2) and most recently in 2015 (GPP3). The latest version reflects the changes that have occurred in legislation…

Freelancing – Are you ready to go solo? - Volume 24, Issue

Freelancing offers an ideal way of making a living for many of us, providing the opportunity to work from home, and be our own boss. However, working for yourself comes with its own set of challenges and is definitely not an easy option. Success is…

The Webscout - Volume 24, Issue

When thinking about the topic of this issue I questioned why for some people business is a source of fun while for others it is not. We all know that factors like time pressure, an inadequate working environment and a lack of variety in our tasks…